Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to the Ultragenyx Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx Pharmaceutical Inc. (RARE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Alkeon Capital Management Panayotis Takis Sparaggis | 3,011,716 | $167,300,824 | +35% | 0.28% |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,978,272 | $109,893,010 | +3% | 3.57% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,576,114 | $87,553,133 | +8% | 0.9% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,525,741 | $84,754,913 | +36% | 0.14% |
| 5. | Alyeska Investment Group Anand Parekh | 1,170,007 | $64,993,889 | +1572% | 0.33% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.63 | 5,000 | Officer, Director | 472,479 | 2019-09-11 | Filing | |
| $52.96 | 1,647 | Officer, Director | 2,559,741 | 2017-08-28 | Filing | |
| $52.40 | 5,853 | Officer, Director | 2,558,094 | 2017-08-28 | Filing | |
| $21.00 | 175,000 | Large Shareholder, Other | 3,260,240 | 2014-01-31 | Filing | |
| $21.00 | 4,500 | Officer | 84,255 | 2014-01-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $52.76 | 7,465 | 92,301 | 2024-10-10 | Filing | ||
| $55.85 | 20,000 | 2,223,985 | 2024-09-03 | Filing | ||
| $56.19 | 91 | 41,551 | 2024-09-03 | Filing | ||
| $50.17 | 20,000 | 2,243,985 | 2024-08-06 | Filing | ||
| $40.98 | 584 | 12,009 | 2024-07-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,673,432 | $414,763,518 | 0% | |
| 2. | 6,887,086 | $329,340,453 | 5.14% | |
| 3. | 5,238,400 | $250,500,292 | 0% | |
| 4. | 4,415,029 | $211,126,686 | 0.03% | |
| 5. | 4,118,008 | $196,923,143 | 0.59% |
News See All
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Ultragenyx Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-2.02505 EPS, expectations were $-1.72.
5 NASDAQ Stocks with Biggest Upside
Based on 12 Wall Street analysts’ ratings in the last three months, Rivian Automotive, Inc. (NASDAQ:RIVN) has a consensus rating of Moderate Buy.
10 Biotech Stocks with Huge Potential
In this article, we will take a look at the 10 biotech stocks with huge potential.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. beats earnings expectations. Reported EPS is $-1.52, expectations were $-1.65. Ultragenyx Pharmaceutical Inc.
15 Best Strong Buy Stocks To Invest In
In this piece, we will take a look at the 15 best strong buy stocks to invest in.
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
Billionaire Hedge Funds
